Early research (Phase 1)Study completedNCT02334501What this trial is testingOpen-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy SubjectsWho this might be right forHealthy Puma Biotechnology, Inc. 15
Not applicableEnded earlyNCT03786107What this trial is testingHER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of NeratinibWho this might be right forHormone Receptor-Positive, HER2-Negative Metastatic Breast CancerMetastatic Cervical Cancer Puma Biotechnology, Inc. 1,583
Early research (Phase 1)Study completedNCT00781430What this trial is testingStudy Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver DiseaseWho this might be right forHepatic Insufficiency Puma Biotechnology, Inc. 27
Testing effectiveness (Phase 2)Study completedNCT00741260What this trial is testingStudy Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast CancerWho this might be right forBreast Cancer Puma Biotechnology, Inc. 105
Testing effectiveness (Phase 2)Study completedNCT02236000What this trial is testingA Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast CancerWho this might be right forBreast Cancer NSABP Foundation Inc 49
Testing effectiveness (Phase 2)WithdrawnNCT04901299What this trial is testingFulvestrant + Neratinib In Breast CancerWho this might be right forStage IV (Metastatic) Breast CancerMetastatic Breast CancerER Positive Breast Cancer+3 more Massachusetts General Hospital
Early research (Phase 1)Study completedNCT00838539What this trial is testingStudy Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid TumorsWho this might be right forNeoplasmsMalignant Carcinoma Puma Biotechnology, Inc. 63
Testing effectiveness (Phase 2)WithdrawnNCT05512182What this trial is testingEfficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/OverexpressionWho this might be right forRecurrent/Advanced Gastric Cancer Yonsei University
Not applicableNot Yet RecruitingNCT07019272What this trial is testingNeratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World StudyWho this might be right forHER2-positive Breast Cancer Hebei Medical University Fourth Hospital 170
Testing effectiveness (Phase 2)Study completedNCT01494662What this trial is testingHKI-272 for HER2-Positive Breast Cancer and Brain MetastasesWho this might be right forBreast Cancer Dana-Farber Cancer Institute 140
Not applicableLooking for participantsNCT06693024What this trial is testingAdjuvant Therapy With Neratinib in HER2 Positive Early Breast CancerWho this might be right forHER2-positive Breast Cancer Shu Wang 2,806
Testing effectiveness (Phase 2)Study completedNCT03094052What this trial is testingIncidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and NeratinibWho this might be right forHER2-positive Breast CancerBreast AdenocarcinomaStage II Breast Cancer AJCC v6 and v7+6 more University of California, San Francisco 11
Testing effectiveness (Phase 2)Ended earlyNCT03101748What this trial is testingNeratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast CancerWho this might be right forBreast Inflammatory CarcinomaLocally Advanced Breast CarcinomaMetastatic Breast Carcinoma+5 more M.D. Anderson Cancer Center 34
Early research (Phase 1)Looking for participantsNCT05274048What this trial is testingNeratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer PatientsWho this might be right forGastric CancerGastrointestinal CancerHER2 Gene Mutation Fox Chase Cancer Center 18
Testing effectiveness (Phase 2)Looking for participantsNCT04886531What this trial is testingTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast CancersWho this might be right forBreast CancerHER2-positive Breast CancerER Positive Breast Cancer+1 more Ruth O'Regan 30
Testing effectiveness (Phase 2)Study completedNCT00777101What this trial is testingStudy Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast CancerWho this might be right forAdvanced Breast CancerBreast Cancer Puma Biotechnology, Inc. 233
Testing effectiveness (Phase 2)Study completedNCT01827267What this trial is testingNeratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung CancerWho this might be right forHER2-mutant Non-Small Cell Lung Cancer Puma Biotechnology, Inc. 62
Early research (Phase 1)Study completedNCT00864487What this trial is testingStudy Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of NeratinibWho this might be right forHealthy Subjects Puma Biotechnology, Inc. 24
Testing effectiveness (Phase 2)WithdrawnNCT04856475What this trial is testingEvaluation of Neratinib for Treatment and Prevention of Subsequent CNS Event(s) in Patients With Brain Metastasis of Advanced HER2 Positive Breast CancerWho this might be right forBreast CancerBrain Metastases Jules Bordet Institute
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07333937What this trial is testingNeratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast CancerWho this might be right forBrest Cancer Xijing Hospital 35